SCHEMBL6508799

SCHEMBL6508799

COC(=O)c1cc2cc(C=O)ccc2o1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.47
HDAC3 O15379 3/20 0.45
HDAC4 P56524 3/20 0.45
HDAC1 Q13547 3/20 0.45
HDAC7 Q8WUI4 3/20 0.45
HDAC2 Q92769 3/20 0.45
HDAC10 Q969S8 3/20 0.45
HDAC11 Q96DB2 3/20 0.45
HDAC8 Q9BY41 3/20 0.45
HDAC6 Q9UBN7 3/20 0.45
HDAC9 Q9UKV0 3/20 0.45
HDAC5 Q9UQL6 3/20 0.45
LMNA P02545 2/20 0.44
TP53 P04637 1/20 0.44
CA12 O43570 1/20 0.44
CA2 P00918 1/20 0.44
CA3 P07451 1/20 0.44
CA6 P23280 1/20 0.44
CA5A P35218 1/20 0.44
CA7 P43166 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1068378 0.84 MAOB (0.49) ALDH1A1CA12CA2CA3CA6
SCHEMBL6273210 0.83 LMNA (0.63) ALDH1A1HDAC3HDAC4HDAC1HDAC7
SCHEMBL2332320 0.81 PIM1 (0.60) ALDH1A1HDAC3HDAC4HDAC1HDAC7
SCHEMBL29950936 0.81 PIM1 (0.60) ALDH1A1HDAC3HDAC4HDAC1HDAC7
SCHEMBL211674 0.80 FLT3 (0.67) ALDH1A1LMNATP53CA12CA2
SCHEMBL1065473 0.80 TAS1R3 (0.55) ALDH1A1LMNATP53CA12CA2
SCHEMBL445684 0.80 LMNA (0.68) ALDH1A1HDAC3HDAC1HDAC2LMNA
SCHEMBL24681539 0.78 TAS1R3 (0.57) ALDH1A1HDAC3HDAC4HDAC1HDAC7
SCHEMBL22276177 0.78 CHRNA7 (0.47) ALDH1A1HDAC3HDAC1HDAC2LMNA
SCHEMBL1066370 0.78 PIM1 (0.66) ALDH1A1LMNATP53CA9MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024039861-A1 2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER OLEMA PHARMACEUTICALS, INC. (US) 2024-02-22 WO disclosed
WO-2005066151-A2 HISTONE DEACETYLASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2005-07-21 WO disclosed
WO-2005066151-A2 HISTONE DEACETYLASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2005-07-21 WO disclosed
US-20050137234-A1 Histone deacetylase inhibitors SYRRX, INC. 2005-06-23 US disclosed
CN-1170827-C Benzofurylpyrone derivatives ������������ʽ���� 2004-10-13 CN disclosed
EP-1063235-B1 BENZOFURYLPYRONE DERIVATIVES TEIJIN LTD (JP) 2004-05-12 EP disclosed
US-20030186976-A1 Benzofurylpyrone derivatives TEIJIN LIMITED, MICROBIAL CHEMISTRY RESEARCH FOUNDATION 2003-10-02 US disclosed
US-6589984-B1 Blood cholesterol and triglycerides (TG) themselves are generally insoluble in blood, and they exist as lipoproteins by binding with apolipoproteins. In the body, triglycerides are biosynthesized primarily in the liver from acetyl CoA as TEIJIN LIMITED (JP) 2003-07-08 US disclosed
CN-1299359-A Benzofurylpyrone derivatives TEIJIN LTD (JP) 2001-06-13 CN disclosed
EP-1063235-A1 BENZOFURYLPYRONE DERIVATIVES TEIJIN LIMITED (JP) 2000-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186976-A1 Benzofurylpyrone derivatives PLIN5, ACSL5, PLIN1 ALDH1A1 1272/4885HDAC3 52/4885HDAC4 169/4885
US-20050137234-A1 Histone deacetylase inhibitors HDAC1, HDAC5, HDAC11 ALDH1A1 1731/4885HDAC3 4/4885HDAC4 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.